Immune checkpoint inhibitors, such as programmed cell death protein 1 (PD-1) and its ligand (PD-L1), have become one of the new standard of care for first- and second-line treatment of advanced hepatocellular carcinoma (12, 13) in recent years, as they continue to demonstrate good efficacy in the treatment of advanced hepatocellular carcinoma. This evidence concerns the gene CD274 and hepatocellular carcinoma.